11 novembre, 2007 22:39

Associated Press 11.08.07, 4:15 PM ET

In a Nov. 7 story about Mentor Corp.'s earnings, The Associated Press reported erroneously that the company has a Botox development program.

Mentor has a botulinum toxin development program. Allergan Inc. makes the branded Botox, which is botulinum toxin type A.

A corrected version of the story appears below.

SANTA BARBARA, Calif. (AP) - Mentor Corp., which makes cosmetic and reconstructive surgery products, said Wednesday its fiscal 2008 second-quarter profit rose 2 percent on higher MemoryGel silicone breast implant sales.

The company earned $9.9 million, or 26 cents per share, compared with profit of $9.7 million, or 22 cents per share, during the same period a year prior. Revenue rose 28 percent to $85.4 million from $66.9 million.

Excluding charges for the buyout of Perouse Plastie and other items, Mentor earned 29 cents per share in the quarter ended Sept. 30.

Analysts polled by Thomson Financial expected profit of 27 cents per share on revenue of $84.5 million.

The company said the sales increase was aided primarily by MemoryGel silicone breast implants.

Selling, general and administrative expenses rose 16 percent to $33.4 million on higher equity compensation expenses and acquisition costs for Perouse Plastie.

Research and development expenses rose 36 percent to $12.2 million. The company's R&D investment supported its botulinum toxin development program, its hyaluronic acid dermal filler development program, its compliance with MemoryGel breast implants post-approval conditions, and the U.S. Food and Drug Administration review of its Contour Profile Gel breast implant application.

Shares of Mentor lost 9 cents to $42.71.